Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies

Abstract

Mutations of RAS oncogenes are responsible for about 30% of all human cancer types, including pancreatic, lung, and colorectal cancers. While KRAS1 is a pseudogene, mutation of KRAS2 (commonly known as KRAS oncogene) is directly or indirectly associated with human cancers. Among the RAS family, KRAS is the most abundant oncogene related to uncontrolled cellular proliferation to generate solid tumors in many types of cancer such as pancreatic carcinoma (over 80%), colon carcinoma (40–50%), lung carcinoma (30–50%), and other types of cancer. Once described as ‘undruggable’, RAS proteins have become ‘druggable’, at least to a certain extent, due to the continuous efforts made during the past four decades. In this account, we discuss the chemistry and biology (wherever available) of the small-molecule inhibitors (synthetic, semi-synthetic, and natural) of KRAS proteins that were published in the past decades. Commercial drugs, as well as investigational molecules from preliminary stages to clinical trials, are categorized and discussed in this study. In summary, this study presents an in-depth discussion of RAS proteins, classifies the RAS superfamily, and describes the molecular mechanism of small-molecule RAS inhibitors

Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action

“…These include molar refractivity, polar surface area, rotatable bonds, etc. Some commonly used small-molecule drugs are aspirin, atenolol, diazepam, diclofenac, ibuprofen, felodipine, omeprazole, phenytoin, and many others [ 22 , 23 , 24 , 25 ]. This review will shed light on the molecular characterization of TNBC, single drug targets, drug combinations, and different small molecules that are targeted to cause regulated or programmed cell death for the treatment of TNBC.…”

Acridine Based N-Acylhydrazone Derivatives as Potential Anticancer Agents: Synthesis, Characterization and ctDNA/HSA Spectroscopic Binding Properties

“…Heterocyclic compounds, as the most important organic compounds, are frequently present in molecules of interest in medicinal chemistry [1][2][3][4][5]. Heterocycles demonstrate pharmacological activity via several mechanisms.…”

“…In 2020, DiFranco and coworkers [9] demonstrated that exposure to a neo-synthetic bis(indolyl)thiazole alkaloid analog, nortopsentin 234, leads to an initial reduction of proliferative and clonogenic potential of colorectal cancer cells. Hamdy et al [10] published the anti-apoptotic Bcl-2-inhibitory activity of synthesized 3-(6-substituted phenyl- [1,2,4]-triazolo [3,4-b]- [1,3,4]-thiadiazol-3-yl)-1H-indoles. Shao et al [11] synthesized and tested aminoindazole derivatives as new irreversible inhibitors of wild-type and gatekeeper mutant FGFR 4 .…”